Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies
Pharmaceuticals · 30.04.2024 · 17 (5) · 578
DOI: 10.3390/ph17050578 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.04.2024. Verfasst von Kirti S Prabhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Centre, Medical Research Centre at Hamad Medical Corporation, Doha, Qatar.
Abstract (Originalsprache)
The growing global burden of malignant tumors with increasing incidence and mortality rates underscores the urgent need for more effective and less toxic therapeutic options. Herbal compounds are being increasingly studied for their potential to meet these needs due to their reduced side effects and significant efficacy. Pristimerin (PS), a triterpenoid from the quinone formamide class derived from the Celastraceae and Hippocrateaceae families, has emerged as a potent anticancer agent. It exhibits broad-spectrum anti-tumor activity across various cancers such as breast, pancreatic, prostate, glioblastoma, colorectal, cervical, and lung cancers. PS modulates several key cellular processes, including apoptosis, autophagy, cell migration and invasion, angiogenesis, and resistance to chemotherapy, targeting crucial signaling pathways such as those involving NF-κB, p53, and STAT3, among others. The main objective of this review is to provide a comprehensive synthesis of the current literature on PS, emphasizing its mechanisms of action and molecular targets with the utmost clarity. It discusses the comparative advantages of PS over current cancer therapies and explores the implications for future research and clinical applications. By delineating the specific pathways and targets affected by PS, this review seeks to offer valuable insights and directions for future research in this field. The information gathered in this review could pave the way for the successful development of PS into a clinically applicable anticancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar.
- Department of Biosciences, Integral University, Lucknow 226026, Uttar Pradesh, India.
- Department of Human Genetics-Precision Medicine in Diabetes, Obesity, and Cancer Program, Sidra Medicine, Doha 26999, Qatar.
- Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar.
- Laboratory of Animal Research Center, Qatar University, Doha 2713, Qatar.
ORCID-Profile: Farina Mujeeb, Ummu Habeeba, Ajaz A Bhat, Shahab Uddin
Förderung
- Medical Research Centre
- Medical Research Centre at Hamad Medical Corporation, Doha, Qatar
Zitieren
APA
Prabhu, K. S., Jessy, S., Kuttikrishnan, S., Mujeeb, F., Mariyam, Z., Habeeba, U., Ahmad, N., Bhat, A. A., & Uddin, S. (2024). Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies. Pharmaceuticals, 17(5), 578. https://doi.org/10.3390/ph17050578
Vancouver
Prabhu KS, Jessy S, Kuttikrishnan S, Mujeeb F, Mariyam Z, Habeeba U, et al. Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies. Pharmaceuticals. 2024;17(5):578. doi:10.3390/ph17050578
BibTeX
@article{Prabhu2024,
author = {Prabhu, Kirti S and Jessy, Serah and Kuttikrishnan, Shilpa and Mujeeb, Farina and Mariyam, Zahwa and Habeeba, Ummu and Ahmad, Nuha and Bhat, Ajaz A and Uddin, Shahab},
title = {Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {5},
pages = {578},
doi = {10.3390/ph17050578}
}
EUVIMED